Caffeine enhances the speed of the recovery of the hypothalamo-pituitary-adrenocortical axis after chronic prednisolone administration in the rat. 1991

H F Marzouk, and J Zuyderwijk, and P Uitterlinden, and P van Koetsveld, and J J Blijd, and E M Abou-Hashim, and M H el-Kannishy, and F H de Jong, and S W Lamberts
Department of Medicine III, Erasmus University, Rotterdam, The Netherlands.

Chronic administration of corticosteroids results in a suppression of the hypothalamo-pituitary-adrenocortical (HPA) axis. The time course of the recovery of the HPA axis depends on the dose and duration of corticosteroid administration. We investigated the recovery of the HPA axis after 14 days of prednisolone administration to rats at a dose of 2.0 mg/rat/day via the drinking water (188 mumol/l). The in vitro corticosterone production by dispersed adrenal cells in response to increasing concentrations of ACTH had recovered 3 days after stopping prednisolone administration. In parallel the initially suppressed plasma corticosterone concentrations had recovered after 3 days, while the pituitary ACTH content had recovered after 5 days. We investigated the possibility to enhance the speed of the recovery of the HPA axis by the simultaneous administration of two drugs with known CRF-stimulating activity via the drinking water. Caffeine in a dose of 100 mg/kg body weight enhanced the recovery of the prednisolone-suppressed HPA axis significantly. One day after the end of prednisolone administration a significant increase in the adrenal weight, in the corticosterone production by dispersed adrenal cells, as well as in the plasma corticosterone concentrations, and in the pituitary ACTH content was observed in the caffeine-treated rats. Chlorimipramine (20 mg/kg body weight), on the other hand, did not influence the prednisolone-mediated suppression of the HPA axis.(ABSTRACT TRUNCATED AT 250 WORDS)

UI MeSH Term Description Entries
D007031 Hypothalamus Ventral part of the DIENCEPHALON extending from the region of the OPTIC CHIASM to the caudal border of the MAMMILLARY BODIES and forming the inferior and lateral walls of the THIRD VENTRICLE. Lamina Terminalis,Preoptico-Hypothalamic Area,Area, Preoptico-Hypothalamic,Areas, Preoptico-Hypothalamic,Preoptico Hypothalamic Area,Preoptico-Hypothalamic Areas
D007700 Kinetics The rate dynamics in chemical or physical systems.
D009929 Organ Size The measurement of an organ in volume, mass, or heaviness. Organ Volume,Organ Weight,Size, Organ,Weight, Organ
D010902 Pituitary Gland A small, unpaired gland situated in the SELLA TURCICA. It is connected to the HYPOTHALAMUS by a short stalk which is called the INFUNDIBULUM. Hypophysis,Hypothalamus, Infundibular,Infundibular Stalk,Infundibular Stem,Infundibulum (Hypophysis),Infundibulum, Hypophyseal,Pituitary Stalk,Hypophyseal Infundibulum,Hypophyseal Stalk,Hypophysis Cerebri,Infundibulum,Cerebri, Hypophysis,Cerebrus, Hypophysis,Gland, Pituitary,Glands, Pituitary,Hypophyseal Stalks,Hypophyses,Hypophysis Cerebrus,Infundibular Hypothalamus,Infundibular Stalks,Infundibulums,Pituitary Glands,Pituitary Stalks,Stalk, Hypophyseal,Stalk, Infundibular,Stalks, Hypophyseal,Stalks, Infundibular
D011239 Prednisolone A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. Di-Adreson-F,Predate,Predonine,Di Adreson F,DiAdresonF
D001835 Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms. Body Weights,Weight, Body,Weights, Body
D002110 Caffeine A methylxanthine naturally occurring in some beverages and also used as a pharmacological agent. Caffeine's most notable pharmacological effect is as a central nervous system stimulant, increasing alertness and producing agitation. It also relaxes SMOOTH MUSCLE, stimulates CARDIAC MUSCLE, stimulates DIURESIS, and appears to be useful in the treatment of some types of headache. Several cellular actions of caffeine have been observed, but it is not entirely clear how each contributes to its pharmacological profile. Among the most important are inhibition of cyclic nucleotide PHOSPHODIESTERASES, antagonism of ADENOSINE RECEPTORS, and modulation of intracellular calcium handling. 1,3,7-Trimethylxanthine,Caffedrine,Coffeinum N,Coffeinum Purrum,Dexitac,Durvitan,No Doz,Percoffedrinol N,Percutaféine,Quick-Pep,Vivarin,Quick Pep,QuickPep
D002997 Clomipramine A tricyclic antidepressant similar to IMIPRAMINE that selectively inhibits the uptake of serotonin in the brain. It is readily absorbed from the gastrointestinal tract and demethylated in the liver to form its primary active metabolite, desmethylclomipramine. Chlorimipramine,Anafranil,Chlomipramine,Clomipramine Hydrochloride,Clomipramine Maleate (1:1),Clomipramine Monohydrochloride,Hydiphen,Hydrochloride, Clomipramine,Monohydrochloride, Clomipramine
D003345 Corticosterone An adrenocortical steroid that has modest but significant activities as a mineralocorticoid and a glucocorticoid. (From Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p1437)
D005260 Female Females

Related Publications

H F Marzouk, and J Zuyderwijk, and P Uitterlinden, and P van Koetsveld, and J J Blijd, and E M Abou-Hashim, and M H el-Kannishy, and F H de Jong, and S W Lamberts
May 1987, The Journal of endocrinology,
H F Marzouk, and J Zuyderwijk, and P Uitterlinden, and P van Koetsveld, and J J Blijd, and E M Abou-Hashim, and M H el-Kannishy, and F H de Jong, and S W Lamberts
May 2006, Psychoneuroendocrinology,
H F Marzouk, and J Zuyderwijk, and P Uitterlinden, and P van Koetsveld, and J J Blijd, and E M Abou-Hashim, and M H el-Kannishy, and F H de Jong, and S W Lamberts
August 1989, The Journal of endocrinology,
H F Marzouk, and J Zuyderwijk, and P Uitterlinden, and P van Koetsveld, and J J Blijd, and E M Abou-Hashim, and M H el-Kannishy, and F H de Jong, and S W Lamberts
October 1984, Neuroendocrinology,
H F Marzouk, and J Zuyderwijk, and P Uitterlinden, and P van Koetsveld, and J J Blijd, and E M Abou-Hashim, and M H el-Kannishy, and F H de Jong, and S W Lamberts
April 2006, Endocrinology,
H F Marzouk, and J Zuyderwijk, and P Uitterlinden, and P van Koetsveld, and J J Blijd, and E M Abou-Hashim, and M H el-Kannishy, and F H de Jong, and S W Lamberts
February 2003, Current opinion in pharmacology,
H F Marzouk, and J Zuyderwijk, and P Uitterlinden, and P van Koetsveld, and J J Blijd, and E M Abou-Hashim, and M H el-Kannishy, and F H de Jong, and S W Lamberts
March 1985, Neuroendocrinology,
H F Marzouk, and J Zuyderwijk, and P Uitterlinden, and P van Koetsveld, and J J Blijd, and E M Abou-Hashim, and M H el-Kannishy, and F H de Jong, and S W Lamberts
September 1996, Trends in endocrinology and metabolism: TEM,
H F Marzouk, and J Zuyderwijk, and P Uitterlinden, and P van Koetsveld, and J J Blijd, and E M Abou-Hashim, and M H el-Kannishy, and F H de Jong, and S W Lamberts
May 2009, Immunology and allergy clinics of North America,
H F Marzouk, and J Zuyderwijk, and P Uitterlinden, and P van Koetsveld, and J J Blijd, and E M Abou-Hashim, and M H el-Kannishy, and F H de Jong, and S W Lamberts
February 1976, British journal of pharmacology,
Copied contents to your clipboard!